Daniel P. Petrylak, MD

Daniel P. Petrylak, MD

Yale University Cancer Center

New Haven, CT

Daniel P. Petrylak, MD, is currently Director of Genitourinary Oncology, Professor of Medicine and of Urology, and Co-Director of the Signal Transduction Program at Yale University Cancer Center. He is a recognized international leader in the field. He completed his medical degree at Case Western Reserve University School of medicine, his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical center, and fellowship at Memorial Sloan Kettering Cancer Center. Dr. Petrylak is the head of the advanced bladder subcommittee in the Southwest Oncology Group (SWOG) Genitourinary Committee. He served principal investigator (PI) or co-PI on seven SWOG clinical trials for genitourinary cancers. Most notably, he served as the PI for a randomized trial that led to the FDA approval of docetaxel in hormone refractory prostate cancer. He also help to design and served as PI for the SPARC trial, an international registration trial evaluating satraplatin as a second line therapy for hormone refractory prostate cancer. Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association from 2003-2011, and for the American Society of Clinical Oncology from 1995-1997 and 2001-2003. He also has served as a committee member for the Devices and Immunologicals section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, and Clinical Cancer Research.

Articles by Daniel P. Petrylak, MD

Checkpoint Inhibitors for NMIBC

Daniel P. Petrylak, MD, provides an overview of immunotherapy treatment options for non-muscle invasive bladder cancer (NMIBC) including BCG, intravesical therapies, and checkpoint inhibitors. He also discusses clinical trials investigating alternative immunotherapy options for NMIBC other than BCG.

Read More

Bladder Cancer and Immunotherapy

Daniel P. Petrylak, MD, reviews data regarding currently-approved immunotherapy agents for bladder cancer in first- and second-line settings. He advocates for future research regarding immunotherapy-based combinations, as well as investigating immunotherapy in earlier stages of the disease.

Read More

Join the GRU Community

- Why Join? -